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ABSTRAK
Latar belakang: Kanker payudara triple negative (TNBC) 
cenderung tumbuh lebih cepat dan memiliki prognosis yang 
buruk dibanding sub-tipe lain. Ekspresi transmembrane 
prostate androgen-induced protein (TMEPAI) yang tinggi 
berhubungan dengan prognosis yang buruk pada pasien 
TNBC. Namun demikian, mekanisme TMEPAI pada proses 
tumoriogenik belum diketahui. Penelitian ini bertujuan 
mengetahui pengaruh TMEPAI terhadap proliferasi sel TNBC.
Metode: CRISPR-Cas9 telah digunakan sebelumnya sebagai 
teknik genome editing untuk membuat galur sel knock-out 
(KO) TMEPAI pada galur sel TNBC, Hs587T. Galur sel Hs587T 
wild-type (WT) dan Hs587T knock-out TMEPAI dikultur 
pada Dulbecco’s modified eagle medium (DMEM) yang 
disuplementasi dengan 10% fetal bovine serum, 1% penicillin-
streptomycin, dan amfoterisin B. Kedua jenis sel dikultur pada 
24-well plates dan dihitung setiap dua hari, kemudian dibuat 
plot kecepatan proliferasi sel. Setelah itu, total RNA dari kedua 
sel tersebut diisolasi untuk pemeriksaan tingkat ekspresi mRNA 
marker proliferasi, Ki-67 dan TGF-β.
Hasil: Laju proliferasi sel menunjukkan galur sel WT-TMEPAI 
tumbuh lebih cepat dibandingkan dengan KO-TMEPAI. Hasil 
ini didukung dengan penurunan tingkat ekspresi mRNA dari 
marker proliferasi, Ki-67 dan TGF-β galur sel KO-TMEPAI.
Kesimpulan: Knock-out TMEPAI menurunkan proliferasi sel 
pada kanker payudara triple negative.
ABSTRACT
Background: Triple negative breast cancer (TNBC) tends 
to grow more rapidly and has poorer prognosis compared 
to others. High expression of transmembrane prostate 
androgen-induced protein (TMEPAI) correlates with poor 
prognosis in TNBC patients. However, the mechanistic role 
of TMEPAI in tumorigenic remains unknown. This study 
aimed to knock-out TMEPAI in TNBC cell line to determine 
its function further in cells proliferation.
Methods: CRISPR-Cas9 has been used previously to knock-
out TMEPAI in Hs857T TNBC cell line. Hs587T TNBC parental 
cell line (wild-type/WT) and TMEPAI knock out Hs 586T cell 
lines were cultured in Dulbecco’s modified eagle medium 
(DMEM) supplemented with 10% fetal bovine serum, 1% 
penicillin-streptomycin and amphotericin B. Both cell lines 
were seeded in 24-well plates and counted every two days, 
then proliferation rates were plotted. Afterwards, total RNA 
were isolated from the cells and Ki-67, and TGF-β mRNA 
expression levels as proliferation markers were determined.
Results: Cell proliferation rates as displayed in growth curve 
plots showed that WT-TMEPAI cell line grew more rapidly 
than KO-TMEPAI. In accordance, mRNA expression levels of 
Ki-67 and TGF-β  were significantly decreased in KO-TMEPAI 
cell line.
Conclusion: Knock-out of TMEPAI attenuates cell 
proliferation in TNBC.
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Triple negative breast cancer (TNBC) presents in 
a small number of patients of 15–25% out of the 
total breast cancer patients.1,2 However, this type of 
breast cancer is related to shorter survival, poorer 
prognosis, and metastasize more frequently in lungs 
and brains compared to other breast cancer sub-
types.1–3 Until now, there is no available targeted 
therapy indicated for TNBC due to lack expressions 
of estrogen, progesterone, and human epidermal 
receptors. The current modality of treatment is 
chemotherapy such as doxorubicin and paclitaxel, 
with no specific targets.3 Unfortunately, this type of 
breast cancer is more prone to develop resistance, 
either intrinsic or acquired to cytotoxic agents.4 
Therefore, a deep and thorough understanding 
for the pathogenesis as well as chemo-resistance 
mechanism is urgent in order to determine a novel 
drug targets for TNBC patients.
Transmembrane prostate androgen-induced 
protein (TMEPAI) is remarkable in TNBC. It 
found highly expressed in 68,8% TNBC patients.2 
Moreover, high expression of TMEPAI correlates 
to poorer prognosis and shorter relapse-free 
survival.5 The importance of TMEPAI in TNBC 
started when Singha et al suggested it as a 
responsible converter for TGF-β from tumor 
suppressor into promotor.6 Further study by 
Singha et al2 discussed about the mechanism 
of TMEPAI in TNBC. TMEPAI inhibits Smad-
dependent pathways of TGF-β and instantly 
promotes non-Smad pathways via PI3K/Akt 
signaling. Previously, Watanabe at al proved how 
TMEPAI works in Smad-dependent pathways 
to inhibit TGF-β signaling. TMEPAI disrupts 
interaction between R-Smad and SARA through 
Smad interaction motif (SIM). Afterwards, 
TMEPAI traps phosphorylated Smad2 and Smad3 
by preventing their translocation into the nucleus. 
Consequently, transcription and translation of 
TGF-β target genes will be stopped.7
In addition, TMEPAI promotes degradation of 
PTEN, thus promotes PI3K/Akt pathways to be 
activated. It resulted in an enhancement of cell 
growth.2 Furthermore, TMEPAI has been proven 
to increase tumorigenic properties in lung 
cancer.8 However, the mechanism of how TMEPAI 
enhances tumorigenic activities in cancer remains 
unknown. Hence, we aimed to investigate the role 
TMEPAI in TNBC to determine its function further 
in cell proliferation, using our previous knock out 
TMEPAI TNBC.
METHODS
Cell culture and cell proliferation rate
Triple negative breast cancer cell line, Hs578T 
was obtained from the American Type Culture 
Collection (ATCC). Hs578T with TMEPAI knock-
out (KO) cells was developed from HS578T 
wild-type (WT) previously using CRISPR-Cas9 
system.9 Both of Hs578T, WT and KO, were 
cultured in Dulbecco’s modified essential 
medium (DMEM, Invitrogen) supplemented with 
10% fetal bovine serum (FBS, Gibco), 10 µg/mL 
insulin, and 100 units/mL of penicillin G and 0.1 
mg/mL of streptomycin sulfate (Wako). Cells 
were maintained in 5% CO2 incubator at 37°C. 
Both cell lines were seeded in same number 
in 24-well plates and counted every two days 
using hemocytometer in 0.4% trypan blue cell 
suspension up to 8 days. Area under the curve 
(AUC) of cell proliferation was calculated by 
connecting the dots which represents number 
of cells in different time points. AUC were 
calculated automatically using GraphPad Prism 
v. 7.0 software (GraphPad Prism, USA).  Doubling 
time for each cell line were also calculated using 
online doubling time calculator.10 All of the 
experiments were conducted three times and 
were duplicated.
RT-PCR
We isolated total RNA using Total RNA Mini Kit 
(Geneaid) for cultured cells, and afterwards, 
converted total  RNA into cDNA using Transcriptor 
First Strand cDNA Synthesis Kit (Roche). RT-
PCR were performed using FastStart Essential 
DNA Green Master (Roche). All primers 
were purchased from the Integrated DNA 
Technologies, Singapore. Primer sequences all of 
the mRNA evaluated were as below: Ki-67 Fwd: 
5’-TCCTTTGGTGGGCACCTAAGACCTG-3’; Ki-67 Rev: 
5’-TGATGGTTGAGGTCGTTCCTTGATG-3’; TGF-β 
Fwd:  5’-TGAACCGGCTTTTCCTGCTTCTCATG-3’; 
TGF-β Rev: 5’-GCGGAAGTCAATGTACAGCTGCCGC-3’. 
β-actin was used as a house-keeping gene 
with primer sequences: β-actin Fwd: 
5’-GCTGGAAGGTGGACAGCGA-3’ and β-actin  Rev: 
5’-GGCATCGTGATGGACTCCG-3’.
Statistical analysis
Data were shown as mean ± standard deviation 
(SD). Statistical analysis was performed with 
independent t-test comparing area under 
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the curve (AUC) for proliferation rate, mRNA 
expressions of Ki-67, and TGF-β of knock-
out cell line versus wild-type. Differences 
were considered statistically significant at 
p<0.05. All the statistical analysis and graphs 
presented were calculated and drawn using 
GraphPad Prism v 7.0 software (GraphPad 
Prism, USA).
RESULTS
Decreased cell proliferation rate in KO-
TMEPAI versus WT-TMEPAI TNBC
KO-TMEPAI (Figure 1A) had  lower cell confluency 
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Figure 1. WT-TMEPAI cells grew more rapidly than KO-TMEPAI Hs587T cells. A) TNBC cell line, Hs578T, with wild-type TMEPAI 
(WT-TMEPAI). B) TNBC cell line, Hs578T, with knock-out TMEPAI (KO-TMEPAI). Cells were taken picture under inverted micro-
scope with 10x magnification. C) Cell proliferation rates of WT-TMEPAI and KO-TMEPAI Hs587T cells were determined using cell 
growth curve plot up to 8 days. D) Area under curve of WT-TMEPAI and KO-TMEPAI cells proliferation rate. E). Doubling time for 
KO-TMEPAI was longer compared with WT-TMEPAI Hs587T cells. All experiments were conducted three times in duplicate. WT: 
wild-type. KO: knock-out. *) p<0.05 after independent t-test comparing wild-type versus knock-out
compared to WT-TMEPAI Hs587T cells (Figure 
1B). In accordance, cell proliferation rate of KO-
TMEPAI was slower than those of WT-TMEPAI 
Hs587T cells (Figure 1C), along with lower area 
under curve (Figure 1D). Doubling time for KO-
TMEPAI was longer than WT-TMEPAI cells  as 
shown in (Figure 1E).
Proliferation marker and TGF-β were 
attenuated in the knock-out TMEPAI Hs587T 
cells
Figure 2A and 2B show alterations of mRNA 
expressions of Ki-67 and TGF-β. Proliferation 
marker, Ki-67 decreased remarkably in KO-
TMEPAI Hs587T cells as well as TGF-β.
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DISCUSSION
It is noteworthy that currently there is no targeted 
therapy registered for triple negative breast 
cancer (TNBC) worldwide. TNBC is counted due 
to its more aggressive behavior, and thus, resulted 
in poorer prognosis as compared to other types of 
breast cancer. Moreover, TNBC frequently occurs 
in young woman.3 Many researchers aimed to 
elucidate the signaling pathways which involved 
in TNBC as a target for novel therapy.
TMEPAI has been suggested to enhance 
tumorigenic activity in breast cancers. Previously, 
there were two reports from Singha2,6 which used 
knock-down TMEPAI TNBC cells to elucidate the 
role of TMEPAI in oncogenic and tumorigenic 
activities of  TNBC. However, their model, that 
used shRNA, could not fully omitted TMEPAI in 
TNBC cells. Therefore, in this study we aimed to 
determine cell proliferation alteration in a fully 
knock-out TMEPAI TNBC cells.
We established knock-out TMEPAI cells in 
previous study using CRISPR-Cas9 systems in 
Hs578T wild-type, one of triple negative cell line.9 
In this study, we showed that KO-TMEPAI cells had 
longer doubling time compared to WT-TMEPAI 
cells. KO-TMEPAI cells also showed a slower 
proliferation rate than that of wild-type TMEPAI 
cell line. This strongly indicated that TMEPAI had 
an important role in cell proliferations of triple 
negative breast cancer. In accordance, previous 
study by Singha et al2 reported that knock-
down TMEPAI attenuated tumorigenic activity. 
TMEPAI was reported by Azami et al. as a pro-
tumoriogenic factor in lung cancer induced by 
TGF-β signaling. It also dominantly depended on 
activated autocrine TGF-β signaling.11
Furthermore, we also evaluated mRNA expression 
levels of TGF-β. It was previously known that 
TGF-β induced TMEPAI expression in genomic 
transcript, as well as proteomic levels.2,6-8 Our 
study differed with previous study which were 
conducted by Singha et al2,6 and Ngunyen et al8 Those study used TGF-β induction in cell 
medium. In our study, we did not add TGF-β 
exogenously. This condition might be due to the 
basal conditions that corresponded to autocrine 
signaling of TGF-β in KO and WT-TMEPAI TNBC 
cells. Our results in KO-TMEPAI cells confirmed 
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Figure 2. Decreased mRNA expressions of A) Ki-67 (normal-
ized to β-actin as housekeeping gene) and B) TGF-β (normal-
ized to β-actin as housekeeping gene) in KO-TMEPAI as com-
pared to WT-TMEPAI. All experiments were performed three 
times in duplicate. WT: wild-type. KO: knock-out. *) p<0,05 af-
ter independent t-test comparing wild-type versus knock out
that mRNA expression levels of TGF-β was 
lower than that of wild-type cells. This indicated 
that the loss of TMEPAI resulted in decreased 
proliferation rates, followed by decreased mRNA 
expressions of TGF-β. The expression of TMEPAI 
was controlled by TGF-β constituvely. However, 
TMEPAI suppressed TGF-β signaling by binding 
to R-Smad competitively with SARA (Smad 
anchor for receptor activation), to refrain R-Smad 
binding and inhibit activation of TGF-β receptor 
kinase.7 It is remain unclear how TMEPAI affects 
cell proliferation.
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In this study, the decrease of T`GF-β mRNA 
expression levels was still inadequate to describe 
the activation of TGF-β that was related to cell 
proliferation signaling. Further studies on TMEPAI 
downstream targets are still needed. On the other 
hand, xenograft models from KO-TMEPAI triple 
negative breast cancer cells should be generated 
in order to determine the role of TMEPAI in TNBC.
Previous study by Singha et al2 reported that tumor 
volumes and weights of triple negative xenografts 
models were less in knock-down TMEPAI group 
compared to the wild-type group after 28 days. 
The result was followed by the decrease in 
proliferation marker, Ki67. In accordance with 
that finding, our KO-TMEPAI TNBC also showed 
a decrease in Ki-67 mRNA expressions compared 
to wild-type cells. Cell proliferation rate and 
confluency supported that finding. As indicated 
before, TMEPAI has pivotal role to alter cancer 
proliferation in triple negative breast cancer.
Therefore, we concluded that TMEPAI attenuates 
cell proliferation in TNBC cells. In support our 
finding, Singha et al2, Watanabe et al7 and Ngunyen et al8 already suggested role of TMEPAI in TGF-β 
signaling pathway through Smad-dependent 
and PI3K/Akt pathways. Although we have not 
investigated in xenograft models and determine 
downstream of TGF-β signaling due to the loss of 
TMEPAI, we suggest that TMEPAI  has a potency 
to affect cancer progression in triple negative 
breast cancer, so that it potentially becomes a 
novel targeted therapy.
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